Autogene cevumeran
Highest phase reached
Phase 2
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Oligonucleotide
- Drug name
- Autogene cevumeran
- a 5 capped single stranded messenger rna mrna construct for the expression of patient specific tumour neoantigens comprising a 5 cap a 5 untranslated region derived from human alpha globin mrna an optimised kozak sequence sequences encoding a secretory signal peptide sec 2 0 transmembrane and cytoplasmic domains of a major histocompatibility complex mhc class i molecule mitd a 3 untranslated region fi and a poly a tail sequences encoding patient specific antigens are inserted between the secretory signal peptide and the transmembrane cytoplasmic encoding domains
- A 5'-capped single-stranded messenger RNA (mRNA) construct for the expression of patient-specific tumour neoantigens comprising a 5'-cap, a 5'-untranslated region derived from human alpha-globin mRNA, an optimised Kozak sequence, sequences encoding a secretory signal peptide (sec 2.0), transmembrane and cytoplasmic domains of a major histocompatibility complex (MHC) Class I molecule (MITD), a 3'-untranslated region (FI) and a poly(A)-tail; sequences encoding patient specific antigens are inserted between the secretory signal peptide and the transmembrane/cytoplasmic encoding domains
- autogene cevumeran
- Autogene cevumeran
- Autogene Cevumeran
- autogene cevumeran [INN]
- AUTOGENE CEVUMERAN [USAN]
- Autogene cevumeran [WHO-DD]
- autogene cevumeran inn
- autogene cevumeran usan
- autogene cevumeran who dd
- bnt 122
- BNT-122
- bnt122
- BNT122
- rg 6180
- RG 6180
- RG-6180
- RNA (recombinant 5′-[1,2-[m7Gm-(5′→5′)-p-[P(R)]-sp-p-G]]-capped 5′-UTR (human α-globin RNA-Kozak)/secretory signal peptide sec2.0-specifying/patient-specific tumor neoantigen-specifying insertion site/major histocompatibility complex class I transmembrane and cytoplasmic domains-specifying/3′-UTR (AES mRNA-mitochondrial 12S rRNA)-containing poly(A)-tailed messenger RO7198457 constant region), inner salt
- rna recombinant 5 1 2 m7gm 5 5 p p r sp p g capped 5 utr human α globin rna kozak secretory signal peptide sec2 0 specifying patient specific tumor neoantigen specifying insertion site major histocompatibility complex class i transmembrane and cytoplasmic domains specifying 3 utr aes mrna mitochondrial 12s rrna containing poly a tailed messenger ro7198457 constant region inner salt
- ro 7198457
- RO-7198457
- ro7198457
- Ro7198457
- RO7198457
- CAS registry numbers
- 2365453-34-3
- ChEMBL ID
- CHEMBL4650376
- FDA ingredient codes (UNII)
- L8HDH9IB06
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -meran
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- Carcinoma, Pancreatic Ductal
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005184
- Subject identifier
- D021441
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002617
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005191
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005192
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
Reported adverse events
- Event
- electrocardiogram t wave abnormal
- Reports
- 1
- Reporting signal score
- 7.3771
- NCT03289962
- NCT03815058
- NCT04267237
- NCT04161755
- NCT05968326
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Sequences
- Component
- Sequence
- Type
- Nucleic Acid
- Sequence
- ggggcgaacuaguauucuucugguccccacagacucagagagaacccgccaccaugagagugauggcccccagaacccugauccugcugcugucuggcgcccuggcccugacagagacaugggccggaagcnaucgugggaauuguggcaggacuggcagugcuggccgugguggugaucggagccgugguggcuaccgugaugugcagacggaaguccagcggaggcaagggcggcagcuacagccaggccgccagcucugauagcgcccagggcagcgacgugucacugacagccuaguaacucgagcugguacugcaugcacgcaaugcuagcugccccuuucccguccuggguaccccgagucucccccgaccucgggucccagguaugcucccaccuccaccugccccacucaccaccucugcuaguuccagacaccucccaagcacgcagcaaugcagcucaaaacgcuuagccuagccacacccccacgggaaacagcagugauuaaccuuuagcaauaaacgaaaguuuaacuaagcuauacuaaccccaggguuggucaauuucgugccagccacaccgagaccugguccagagucgcuagccgcgucgcuaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
Related records
Trials (7)
- A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
- A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
- A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
- A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
In development for (8)
- Colorectal cancer Phase 2
- Exocrine pancreatic carcinoma Phase 2
- Head and neck cancer Phase 1
- Melanoma Phase 2
- Metastatic melanoma Phase 2
- Neoplasm Phase 1
- Non-small cell lung carcinoma Phase 2
- Pancreatic ductal adenocarcinoma Phase 2